AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC1001 Low
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPC3001
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPC4001
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPC4002
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06212648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Drugs for clinical trials are orally administered once a day after breakfast.~After randomization, the drug for clinical trials is taken once a day (total of 4 tablets) for 8 weeks.
Study NCT06182566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Convergent ablation
Description: Staged hybrid ablation with CONVERGENT epicardial ablation with ablation of the ligament of Marshall and left atrial appendage clip, followed in second stage by endocardial catheter ablation including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
Study NCT06182566 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein isolation using commercially available catheters; including pulmonary vein isolation and posterior wall ablation with roof and inferior posterior lines in addition to targeting and touching up any areas with signals at the posterior wall
Study NCT06443619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral USG-deep SAPB with glucose
Description: patients will receive unilateral USG-deep SAPB ; 15 ml 0.5 % isobaric bupivacaine with addition of 15ml glucose 10% to (30 ml total volume).
Study NCT06443619 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral USG-deep SAPB without glucose
Description: will receive unilateral USG-deep SAPB; 15ml 0.5% isobaric bupivacaine to be diluted with 15ml isotonic saline0.9% (30 ml total volume).
Study NCT06601998 — intervention group
Intervention type: OTHER
Intervention: Blood samples and Oropharyngeal swab
Description: Blood samples: EDTA-plasma (proteome, metabolome and lipidome) and PBMCs (transcriptome, epigenome, immune-phenotype and genetic polymorphism)
Study NCT06601998 — intervention group
Intervention type: OTHER
Intervention: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
Description: * Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.~* ECG, Heart ultrasound and cardiopulmonary exercise stress testing:~  * NYHA~ * Rhythm or conduction abnormality (yes/no)~ * Left ventricular ejection fraction (%)~ * VO2Max
Study NCT04970199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser application on acupoints
Description: laser acupuncture
Study NCT04970199 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: laser application on acupoints
Description: laser acupuncture
Study NCT05956470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation and breathing program : Sudarshan Kriya Yoga (SKY)
Description: The SKY sessions (3x1,5 h on consecutive days) included online instruction in gentle stretches ('office yoga' in a sitting position), specific breathing exercises and meditation, and discussion of cognitive/behavioral coping skills. After the 3-day program, participants asked to practice the techniques once a day for about 30 min. In addition, there were weekly group exercise sessions of 1 hour where all participants were asked to join.
Study NCT05956470 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management education
Description: This control intervention included viewing of educational videos on stress management and group discussions, where the sessions were equal in length to the SKY intervention. There were also weekly follow-up sessions as in the SKY group where the educational points were reviewed and experiences of the subjects during the previous week was discussed.
Study NCT04881695 — intervention group
Intervention type: OTHER
Intervention: Questionary patients
Description: The patients will answer 1 questionnaire consisting of 5 parts :~* General (demographic information)~* Desire for a child~* Hospital Anxiety and Depression scale~* Sexual life~* Additional questions regarding medical care
Study NCT04881695 — intervention group
Intervention type: OTHER
Intervention: Questionary controls
Description: Witnesses will complete 1 survey containing 4 parts:~* General (demographic information)~* Desire to have a child~* Hospital Anxiety and Depression scale~* Sexual life
Study NCT05171036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: * Group 1 Maintenance of autonomy: Patients in group 1 have no cardiovascular disorders, possibly some cognitive deficits but do not reside in a protected unit.~* Group 2 Prevention of the risk of falls: Patients in group 2 have no cardiovascular problems, possibly some cognitive problems, but can finally follow the indications of the cognitive assessment in the form developped for the study.~* Group 3 Prevention of the risk of falls and monitoring of cardiovascular disorders in the absence of cognitive impairment: Patients in group 3 have had a recent, and currently stabilised, cardiovascular event that may justify exercise reconditioning.~* Group 4 Prevention of the risk of falls and disorientation in a context of cognitive deficit: Patients in group 4 have moderate to severe cognitive disorders, or have Alzheimer's disease or a related disease at a stage of the disease requiring special attention.
Study NCT04781608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: English: In It Together (IIT)
Description: Digital intervention program that consists of 4 modules, to be completed 1 week apart. The modules consist of psychoeducation, as well as acceptance and commitment therapy-inspired activities.
Study NCT05856383 — intervention group
Intervention type: DRUG
Intervention: Inetetamab Combined With Pyrotinib and Vinorelbine
Description: Inetetamab Combined With Pyrotinib and Vinorelbine
Study NCT04831827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVR Reminder
Description: Participants will receive an interactive voice reminder (IVR) to complete mt-sDNA screening at day 7 and 21.
Study NCT04831827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone call from research team
Description: Patients will receive a scripted phone call from the research team to remind them to complete the mt-sDNA screening at day 7 and 21.
Study NCT04831827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EHR Portal message
Description: Patients will receive an EHR patient portal message with a scripted message to remind them to complete the mt-sDNA screening at day 7 and 21.
Study NCT06171334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The intervention consists in Remote Ischemic conditioning (RIC), one session of 40-minutes duration per day for 12 months. The procedure will be performed by using an electric auto-control device by SnapDx Inc (Calgary, Canada) with a blood pressure cuff that inflates up to a pressure of 200 mmHg during the ischemic period. Participant will self-administer the RIC procedure at their home. The device records and documents each RIC cycle.
Study NCT05700500 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shockwave therapy, barbotage and infiltration
Description: ultrasound guided interventions
Study NCT06149585 — intervention group
Intervention type: OTHER
Intervention: Microbial Sampling
Description: Pool microbial sampling will be performed and changes in the microbiome will be evaluated and compared for differences
Study NCT05991336 — intervention group
Intervention type: GENETIC
Intervention: Gene therapy
Description: Autologous edited hematopoietic stem cell transplantation
Study NCT06083870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oba01
Description: Oba01 0.15, 0.5, 0.75, 1.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
Study NCT05855369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trigeminal Nerve Stimulation (TNS)
Description: Non-invasive, pain-free, low-level electrical stimulation to the forehead to modulate the trigeminal nerve and enhance smell function through activation of the highly connected olfactory-intranasal trigeminal brain circuits.
Study NCT05855369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Smell Training (ST)
Description: Sniffing various higher intensity odorant chemicals while performing odor-related cognitive tasks. 16 odorant chemicals will be used for training including: 2 phenyl ethanol, eugenol, lemon, eucalyptus, cinnamon, peppermint, coffee, mandarin, lavender, vanilla, lilac, ginger, chocolate, thyme, banana, and bacon.
Study NCT05855369 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Smell Training (PBO)
Description: Sniffing the same lower intensity odorant chemicals (i.e. N-butanol and 2-phenyl ethanol) over the course of the trial and performing no odor-related cognitive tasks.
Study NCT06390059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the patient by means of insulated transducer arrays. The NovoTTF-200T produces TTFields that exert electric forces intended to disrupt cancer cell division.~TTFields at 150 kHz application will be continuous for at least 18 hours a day on average. TTFields will be continued until disease progression according to RECISTv1.1 or loss of clinical benefit.
Study NCT06390059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study NCT06390059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study NCT06390059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study NCT05758831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perfusion of treatment Rituximab
Description: Perfusion of treatment (Mabthera®, Truxima®, Rixathon®, Ruxience®)
Study NCT05758831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion of treatment Ocrelizumab
Description: Perfusion of treatment (Ocrevus®)
Study NCT05760157 — intervention group
Intervention type: OTHER
Intervention: Possible risk factors of heart failure
Description: Demographic data, previous medical history data, physical examination, ECG examination, blood routine, blood biochemistry, the peak value of myocardial injury markers, serum markers of heart failure, high-sensitivity C-reactive protein Coronary angiography, interventional treatment, microcirculation resistance index caIMR calculation based on coronary angiography Doppler echocardiography, medication during hospitalization, NYHA cardiac function grading before discharge, and 6-minute walk test before discharge.
Study NCT05056870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology for Astigmatism
Description: TEST
Study NCT05056870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day with HydraLuxe Technology
Description: CONTROL
Study NCT05487404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-629
Description: 3 oral doses of ADX-629 600 milligrams
Study NCT06176599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenxiao Yuning decoction
Description: Astragalus 30g, Radix Pseudostellariae 15g, Rehmannia glutinosa 15g, Rhodiola rosea 12g，Cimicifuga 15g，Cuttlebone 15g，Poria 15g，Cicada degeneration 9g，Rheum palmatum 6g.
Study NCT06176599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Study NCT06176599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic treatment
Description: (i) Diabetes education: all study participants were given dietary guidance for diabetic nephropathy, low-fat, high-quality, low-protein diet, and restricted sodium intake; maintain emotional stability, quit smoking and alcohol, and exercise appropriately; (ii) control of blood glucose: all study participants routinely received hypoglycaemic treatment, hypoglycaemic measures are not limited (including oral hypoglycaemic drugs or insulin injection); (iii) Control of lipids: study participants with substandard lipids routinely receive lipid-lowering treatment; (iv) Control of blood pressure: those with blood pressure \&gt;140/90 mmHg should be treated with antihypertensive drugs to control blood pressure, and antihypertensive measures are not limited (CCB class, ACEI or ARB class, α, β-blockers, diuretics, etc.); ⑤ Other symptomatic treatment.
Study NCT05694325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peripheral blood and bone marrow withdrawal
Description: samples evaluation
Study NCT05571527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma treatment
Description: Patients receive platelet-rich plasma via injection into the vaginal area.
Study NCT05571527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Hyaluronic Acid supplement
Description: Patients receive Vaginal Hyaluronic Acid supplement for 10 days, then once a week for 3 months.
Study NCT06484959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assigned Interventions
Description: Assigned Interventions
Study NCT04871737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant NDV Vectored Vaccine for SARS-CoV-2
Description: Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2
Study NCT05487404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 oral doses of placebo
Study NCT06448338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyDiaMate
Description: MyDiaMate program
Study NCT04105790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy with Mindfulness classes
Description: The standard CBTm protocol is comprised of four 90-minute classes offered virtually via videoconferencing once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
Study NCT04840979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-ER176
Description: 11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
Study NCT04840979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-ER176
Description: 11C-ER176 is a novel TSPO radioligand that was developed because of its relative insensitivity to the rs6971 polymorphism. Increased TSPO signal on PET is associated with activation of microglia in the brain. The radioligand will be administered in tracer doses at activity of up to 20 mCi (740 MBq), IV, total of one injection. A single dose of radioligand will be injected over 1 minute.
Study NCT04840979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
Study NCT04840979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
Study NCT05390242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic study
Description: Candidates undergo a radiographic study (Orthopantomography and Implant periapical radiography)
Study NCT06030232 — intervention group
Intervention type: DEVICE
Intervention: Therasphere
Description: Transarterial radioembolization
Study NCT05040204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Monosaccharide Powder
Description: Monosaccharide powder dissolved in water.
Study NCT05040204 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo (glucose powder)
Study NCT05318924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ghrelin
Description: Participants will receive an infusion that is intended to raise ghrelin level up to a steady plateau.
Study NCT05318924 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a saline infusion as the placebo control condition.
Study NCT05233683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: Caudal block will be performed in lateral position with 0.25% bupivacaine in the dose of 0.75 ml/kg containing 1 mic/kg dexmedetomidine. The patients will be turned back to the supine position after the block placement and the head of the patient will be placed in the neutral position. Paracetamol suppository will also be inserted per rectum in the dose of 15 mg/kg before the start of surgery. The surgery will be started 10 minutes after block placement to allow adequate time for the block to be effective.
Study NCT05215067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: IV infusion,Specified dose on specified days
Study NCT05215067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion,Specified dose on specified days
Study NCT04712994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Optimization Interventions
Description: A bundle of strategies (video-based PrEP counselling, HIV Self-Testing \[HIVST\] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.
Study NCT05852132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pars plana vitrectomy(PPV)
Description: Vitrectomy was performed for severe non-proliferative diabetic retinopathy, but panretinal photocoagulation(PRP) was not performed
Study NCT05852132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP)
Description: PPV was performed for severe non-proliferative diabetic retinopathy with PRP.
Study NCT05852132 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Panretinal photocoagulation(PRP)
Description: Only PRP was used for severe non-proliferative diabetic retinopathy.